Mihriban Karaayvaz, PhD
Lerner Research Institute,
9500 Euclid Avenue, Cleveland, Ohio 44195
Our laboratory focuses on understanding the early events in breast cancer development. Two main areas of interest are: (1) studying the somatic genomics of breast cancer in individuals with germline BRCA1/2 predisposing mutations and (2) investigating how tumor heterogeneity contributes to triple-negative breast cancer development and treatment response. We employ state-of-the-art single cell approaches to dissect molecular heterogeneity in pre-malignant and malignant lesions of the breast. Our goal is to leverage the knowledge gained from these studies and develop innovative strategies for breast cancer chemoprevention and treatment.
With a grant from the American Cancer Society, Dr. Karaayvaz’s team will investigate the molecular connections linking BRCA2 to breast cancer development with the goal of developing innovative strategies for breast cancer risk assessment and prevention.